Loading
Gritstone bio
Neoantigen-vaccine pioneer (GRANITE, SLATE) that ran out of money and filed for bankruptcy in October 2024; a cautionary tale for the personalised-vaccine field.
Overview
Gritstone's GRANITE individualised neoantigen vaccine (adenoviral prime, samRNA boost) showed a molecular-response signal in a phase 2/3 colorectal cancer maintenance trial but not enough to fund completion. Chapter 11 filing 10 October 2024; assets sold at auction (Seattle Project Corp. and others) for about $21M in December 2024.
Headquarters
Emeryville, CA, US
Scorecard
All companies#313of 1244 companies, score 13
- phase 3 +6
- modalities +2
- registry trials +5
0 approved, 2 in phase 3, 0 earlier, 0 targets, 6 registry studies. Formula on the scorecards page.
Type
Website
Phase 3vaccine
GRT-C901 is an experimental cancer vaccine from Seattle Project in phase 3 trials for colorectal cancer, with its target not yet stated publicly.
Phase 3vaccine
GRT-R902 is an experimental cancer vaccine from Seattle Project in phase 3 trials for colorectal cancer, with its target not yet stated publicly.
Similar pages
- TrialA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Shares GRT-C901, GRT-R902, Colorectal cancer.
- CompanyTareBio
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- CompanyNykode Therapeutics
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- CompanyCureVac
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- PersonNina Bhardwaj
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- CompanyEvaxion
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- CompanyAdventris Pharmaceuticals
- TreatmentDCVax-L
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.